American Healthcare System 1 - 0 Europe
When it comes to pricing and access, the European healthcare system is losing. The criticisms levelled against the US healthcare system are well rehearsed: It has too many players, it is dizzyingly complex, inefficient and expensive. On the surface, Europe’s healthcare systems look positively harmonious by comparison, more so given the moves underway to facilitate future cross-collaboration.
Is the US market ready for value-based contracting?
Market access in the US has seen a sharp rise in the number and complexity of stakeholders. From patients to prescribers, payers to policymakers, pharma companies now must demonstrate the value of their drugs to a much wider audience.
As a result, one area that has attracted much attention is value-based contracting – or, put simply, a new method of pricing in which payment is made based on the performance of their drug and the outcomes it generates for patients.
Many admirers claim this new pricing method, and increased emphasis on the performance of drugs, could be the saving grace that pharma needs to combat rising healthcare costs and restore public trust. However, as we explore in our latest white paper, is the US market ready for value-based contracting? Or does it still have a long way to go…
Download your copy here
US Pharma Peers Into The Unknown
Despite many bumps in the road and a lack of clear direction, the US healthcare ecosystem always finds a way to deliver its goal – improving the health and well-being of every American. With political, policy and funding uncertainty – and mounting pressures on the US healthcare system to deliver improved outcomes and reduce costs – all stakeholders and contributors are facing significant challenges. We spoke to speaker John Bardi, VP, Public Affairs, Otsuka about the future of market access and reimbursement in the US.
Trends in real-world evidence: Unlocking the data
The ‘evidence revolution’ currently taking place in pharma has the potential to leave an unprecedented impact on the healthcare system worldwide. How best to keep-up, adapt and make the most of the great range of opportunities being presented is now at the heart of how many companies are planning for the future.
For more information on how real-world evidence impacts each part of the drug life cycle, full case studies from tech innovators and an in depth interview with ex-commissioner of the FDA – download your copy today!
Download your copy here